Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
vormatrogine · 1 trial · 3 indications
Incidence and severity of TEAEs including discontinuation of study drug due to TEAEs
| Arm | Type | Description |
|---|---|---|
| Open-label 30 mg/day vormatrogine for up to 2 years | EXPERIMENTAL | Participants who meet all eligibility criteria will receive 30 mg of vormatrogine for up to 2 years. |
| Name | Type | Description |
|---|---|---|
| vormatrogine | DRUG | Once daily oral |
Inclusion Criteria: * Participant who completed an eligible clinical trial (unless agreed by the sponsor medical monitor), including PRAX-628-212, PRAX-628-321 or other vormatrigine trials, or participant who has received vormatrigine outside of an eligible clinical trial (such as an expanded acces...
Vormatrogine is an investigational small molecule being developed for epilepsy, specifically for tonic-clonic seizures. It is currently in Phase 3 clinical development for this indication.
Vormatrogine targets voltage-gated sodium channels (VGSCs), which are involved in the generation and propagation of action potentials in neurons. By modulating these channels, vormatrogine aims to reduce abnormal electrical activity associated with seizures.
Vormatrogine is being developed by Praxis Precision Medicines, Inc., a biopharmaceutical company. The company's stock is traded under the ticker symbol PRAX.
Vormatrogine is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities.
Vormatrogine is being evaluated in a Phase 3 clinical trial (NCT07287163) enrolling adult patients with epilepsy, including those with tonic-clonic seizures. The trial is enrolling by invitation and aims to enroll approximately 700 participants across multiple countries.